Similar articles for PMID: 29275321

Year	Number of Results
2008	4
2009	1
2010	1
2011	3
2012	5
2013	7
2014	4
2015	8
2016	4
2017	4
2018	2
2021	1
2022	1
2024	0

1

Comparison of Thoracic Radiotherapy Efficacy Between Patients With and Without EGFR-mutated Lung Adenocarcinoma.

Li MH, Tsai JT, Ting LL, Lin JC, Liu YC. Li MH, et al. In Vivo. 2018 Jan-Feb;32(1):203-209. doi: 10.21873/invivo.11226. In Vivo. 2018. PMID: 29275321 Free PMC article.

2

Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.

Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, Chang YC, Yu CJ, Yang CH, Yang PC. Gow CH, et al. Clin Cancer Res. 2008 Jan 1;14(1):162-8. doi: 10.1158/1078-0432.CCR-07-1468. Clin Cancer Res. 2008. PMID: 18172267

3

The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma.

Li B, Sun SZ, Yang M, Shi JL, Xu W, Wang XF, Song MM, Chen HM. Li B, et al. J Neurooncol. 2015 Aug;124(1):79-85. doi: 10.1007/s11060-015-1776-3. Epub 2015 Jun 7. J Neurooncol. 2015. PMID: 26050023

4

Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.

Wang Y, Li RQ, Ai YQ, Zhang J, Zhao PZ, Li YF, He WJ, Xia YX, Li WH. Wang Y, et al. Clin Transl Oncol. 2015 Sep;17(9):727-36. doi: 10.1007/s12094-015-1300-4. Epub 2015 Jun 4. Clin Transl Oncol. 2015. PMID: 26041721

5

Epidermal Growth Factor Receptor Mutation Status and Treatment Outcome for R0-Resected Patients with Stage 3 Non-small Cell Lung Cancer.

Liu SR, Qiu B, Yang H, Liang Y, Wang F, Liu SL, Chen ZL, Zhang L, Liu MZ, Wang SY, Lin LF, Liu H. Liu SR, et al. Ann Surg Oncol. 2016 Jun;23(6):2115-22. doi: 10.1245/s10434-015-5076-0. Epub 2016 Feb 17. Ann Surg Oncol. 2016. PMID: 26887852

6

Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.

Imai H, Shukuya T, Takahashi T, Fujiwara S, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Harada H, Endo M, Nakajima T, Yamamoto N. Imai H, et al. Anticancer Res. 2013 Aug;33(8):3279-84. Anticancer Res. 2013. PMID: 23898092

7

Association between EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma.

Hirata H, Nakamura K, Kunitake N, Shioyama Y, Sasaki T, Ohga S, Nonoshita T, Yoshitake T, Asai K, Inoue K, Nagashima A, Ono M, Honda H. Hirata H, et al. Anticancer Res. 2013 Apr;33(4):1649-55. Anticancer Res. 2013. PMID: 23564810

8

CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung.

Ozkan E, West A, Dedelow JA, Chu BF, Zhao W, Yildiz VO, Otterson GA, Shilo K, Ghosh S, King M, White RD, Erdal BS. Ozkan E, et al. AJR Am J Roentgenol. 2015 Nov;205(5):1016-25. doi: 10.2214/AJR.14.14147. AJR Am J Roentgenol. 2015. PMID: 26496549

9

CT Features of Epidermal Growth Factor Receptor-Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma.

Hasegawa M, Sakai F, Ishikawa R, Kimura F, Ishida H, Kobayashi K. Hasegawa M, et al. J Thorac Oncol. 2016 Jun;11(6):819-26. doi: 10.1016/j.jtho.2016.02.010. Epub 2016 Feb 23. J Thorac Oncol. 2016. PMID: 26917231 Free article.

10

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R; Spanish Lung Cancer Group. Karachaliou N, et al. JAMA Oncol. 2015 May;1(2):149-57. doi: 10.1001/jamaoncol.2014.257. JAMA Oncol. 2015. PMID: 26181014 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

41 results

Results by year